SAN DIEGO, October 1, 2022 – Meet Antonius Schuh, Ph.D. (CEO), and Andreas Klostermann, Ph.D. (CSO) for an update on selectION’s best-in-class ion channel blockers and the status of the clinical work.
Site Search
Recent News
- selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
- Meet selectION, Inc. at the BIO International Convention in San Diego, CA, on June 3rd to 6th, 2024
- selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis